A 65‐year‐old man presented with progessive dysphagia, which proved to be the first clinical manifestation of a periperal lung carcinoma (secondary to a submucosal metatasis in the esophagus). The lung tumor, hidden by the diaphragm on chest x‐ray, was not suspected until a thoracotomy was done. Although dysphagia is known to be the first manifestation of bron‐chogenic carcinomas, such presentation in a case of a peripheral lung carcinoma has not been well described. This case is reported with a review of the literature for cases with dysphagia secondary to a metastatic tumor in the esophagus.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第18861号 / 医博第3972号 / 新制||医||1008(附属図書館) / 31812 / 京都大学大学院医学研究科医学専攻 / (主査)教授 武藤 学, 教授 野田 亮, 教授 小川 誠司 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Abstract Aptosis denotes a biochemically and morphologically distinct chain of events leading to self-destruction of cell. It is pivotal in the maintenance of tissue homeostasis and also plays a role in neoplasm. In this work, the extent of apoptosis and apoptosis regulating proteins and factors was studied in a total of 94 patients operated for lung carcinoma, including 56 small cell lung carcinomas (SCLC) and 38 large cell lung carcinomas (LCLC). The extent of apoptosis was determined by detecting and counting the relative and absolute numbers of apoptotic cells and bodies using 3'- end labelling of the apoptotic DNA. The extent of apoptosis in SCLC was compared with the cell proliferation activity as determined by Ki-67 immunohistochemistry, with the volume density of necrosis and with the occurrence of immunohistochemically detectable p53 and bcl-2 proteins. In order to test the hypothesis that increased apoptotic activity is connected with neuroendocrine differentiation and with low differentiation degree in LCLC and that it is regulated by bcl-2 family proteins, the extent of apoptosis and tumour necrosis was analysed in relation to the expression of bcl-2 family proteins bcl-2, mcl-1, bax and bak. Apoptosis, tumour infiltrating lymphocytes (TILs), and angiogenesis are important factors that contribute to tumour growth. In the present study immunohistochemical methods were used to investigate the relationships of these factors and their role in the prognosis of the patients with LCLC and SCLC. A remarkably high apoptotic activity was detected in both SCLC and LCLC. The mean apoptotic index in SCLC was 2.70 % and in LCLC 2.49 %. Exceptionally high proliferation activity and high percentage of tumour necrosis was seen in SCLC. 58 % of SCLC showed more than 40 % of Ki-67 positive nuclei, and tumour necrosis was seen in 83 % of the cases. P53 protein accumulation was detected in 38 % and bcl-2 expression in 50 % of SCLC. The extent of apoptosis in SCLC was inversely related to tumour necrosis and p53 protein accumulation. In LCLC, bcl-2 expression was detected in 40 % of the cases. It was associated with neuroendocrine differentiation and predicted favourable prognosis of the patients. A high number of T cells and macrophages with a small number of B cells was detected in both SCLC and LCLC. The occurrence of intratumoural cytotoxic CD8 cells was associated with the occurrence of apoptotic bodies in SCLC. The increased number of intratumoural T cells, CD8-positive cells and macrophages predicted favourable prognosis of the patients with SCLC. In LCLC, an increased number of B cells and macrophages, but not T cells, was associated with better survival. Iaddition to tumour cells, numerous apoptotic bodies could also be found within alveolar macrophages within and close to tumour tissue. In order to test whether such cells could be found in sputum smears and if their presence could be utilised as a marker of malignancy in tumour diagnosis, the occurrence of alveolar macrophages with apoptotic bodies (AMWABs) was analysed in 84 sputum samples and 13 broncho-alveolar lavage (BAL) specimens from patients with and without lung carcinoma. AMWABs could be found in cytological samples of the patients with lung carcinoma. In sputum and BAL specimens, enhanced apoptosis, as measured by an increased number of AMWABs reflected and was indicative of malignancy. This was also true for cytological specimens of the patients even when the actual malignant cells were not found. Therefore the AMWABs served as a marker of pulmonary malignancy.

La cachexie est un syndrome clinique et métabolique caractérisé par une perte de tissu adipeux et de tissu musculaire, fréquemment observé chez les patients atteints de cancer. La myostatine (Mstn) régule négativement la masse musculaire. Bien que la régulation des mécanismes moléculaires impliqués dans le contrôle de la masse musculaire joue un rôle central dans la cachexie associée au cancer, les relations existant entre la Mstn et les mécanismes physiopathologiques restent largement inconnues. Suite à l’inoculation de cellules Lewis lung carcinoma (LLC) à des souris, nous avons montré que l’invalidation du gène de la Mstn (souris Mstn-/-) confère une résistance au développement de la cachexie associée au cancer par rapport à des souris sauvages. La déficience en Mstn prévient la perte de masse musculaire et réduit la croissance tumorale, 35 jours après l’injection des cellules LLC, et est associée à un allongement de la durée de vie des souris. L’invalidation du gène de la Mstn provoque aussi une augmentation de l’apoptose des cellules LLC et une diminution de l'expression de gènes impliqués dans la prolifération et le métabolisme tumoraux. L’activation des systèmes protéolytiques ubiquitine-protéasome et autophagie-lysosome, due au développement tumoral, est réduite voire supprimée dans le muscle des souris Mstn-/-. L’accumulation de céramides intramusculaires, un sphingolipide formé suite à une lipolyse exacerbée, est corrélée à la perte de masse musculaire, suggérant que les céramides pourraient être un médiateur cellulaire impliqué dans la cachexie associée au cancer. Ces résultats montrent que la Mstn joue un rôle essentiel dans la cachexie associée au cancer / Cachexia is a complex clinical and metabolic syndrome, whose definition is imprecise, characterized by an uncontrolled loss of adipose tissue and skeletal muscle mass, frequently observed in cancer patients, and leading to death in 25% of cancer patients. Myostatin (Mstn) is a negative regulator of skeletal muscle mass and a critical determinant of skeletal muscle homeostasis. Although the regulation of the molecular mechanisms involved in the control of skeletal muscle mass plays a central role in the pathogenesis of cancer cachexia, the relationships between Mstn and the pathophysiological mechanisms remain largely unknown. Following subcutaneous inoculation of Lewis lung carcinoma cells (LLC) in mice, we showed that the Mstn gene inactivation (Mstn-/- mice) confers resistance to the development of cancer cachexia, compared to wild type mice. Mstn deficiency prevents the loss of skeletal muscle mass and reduces tumor growth, 35 days after the inoculation of LLC cells, and this is associated with a longer life of mice. Mstn gene inactivation also causes an increased apoptosis of LLC cells and decreases expression of genes involved in tumor proliferation and metabolism. Activation of ubiquitin-proteasome and autophagy-lysosome proteolytic systems, triggered by tumor growth is significantly reduced or suppressed in skeletal muscle of Mstn-/- mice. Accumulation of intramuscular ceramides, a sphingolipid synthesized due to excessive lipolysis, is correlated with the loss of muscle mass, suggesting that ceramides may be a cellular mediator involved in the pathogenesis of cancer cachexia. These results show that Mstn plays a critical role in the pathogenesis of cancer cachexia

O carcinoma mucoepidermóide de pulmão, um tipo histológico que deriva das glândulas mucosas traqueobrônquicas, manifesta-se com sintomas obstrutivos e tende a comprometer a traqueia. Com finalidade curativa ou paliativa da doença, atualmente há uma forte tendência na oncologia em desenvolver estratégias terapêuticas que visam à administração de compostos com elevado potencial de otimizar o efeito do tratamento com a radiação ionizante, de modo a aumentar a morte de células tumorais e preservar íntegras as células dos tecidos sadios adjacentes. A intensa busca por tais estratégias evidenciou resultados promissores apresentados pelo composto denominado Resveratrol (3,4,5-trihidroxiestilbeno), tornando-o amplamente divulgado e alvo de intensas pesquisas. O principal objetivo do presente estudo foi determinar o efeito do resveratrol em cultura celular de carcinoma mucoepidermóide de pulmão exposta a diferentes doses de radiação ionizante. Para tal, os estudos de citotoxicidade utilizando o método de incorporação do vermelho neutro, e da determinação da dose letal 50 % (DL50) da radiação ionizante, foram realizados em cultura de células da linhagem NCI-H292 [H292] (ATCC® CRL-1848TM), CCIAL069. Com base nos resultados do IC50% (401,5 μM) e da DL50 (693 Gy) foram realizados o teste in vitro do micronúcleo e os ensaios para avaliar o efeito do resveratrol no ciclo celular, reparo da lesão no DNA e processo de lesão radioinduzida, necrose e apoptose celular. Os resultados evidenciaram que o resveratrol na concentração de 30 μM apresenta uma importante capacidade em promover danos às células NCI-H292 após 24 h da irradiação. / Mucoepidermoid lung carcinoma is a histological type that derives from the tracheobronchial mucous glands. It is manifested by trachea symptoms. Curative or palliative purpose for the disease, nowadays presents a strong oncology tendency to develop therapeutic strategies aimed at the administration of high potential compounds to improve the ionizing radiation treatments, so as to increase the radiation effects on tumor cells while minimizing these effects to surrounding normal tissues. The intensive search for such strategies showed promising results by the compound called Resveratrol, making it widely available and subject of many studies. The main of this study was to determine in vitro resveratrol effect in mucoepidermoid lung carcinoma cells NCI-H292 [H292] (ATCC® CRL-1848TM), CCIAL069, exposed to ionizing radiation doses. For this purpose, there were performed in vitro cytotoxicity studies by neutral red uptake assay, as well as the lethal dose 50 % (LD50) of ionizing radiation. On the basis of the IC50% (401.5 μM) and LD50 (693 Gy) results, there were performed in vitro micronucleus test and other tests in order to evaluate the cell cycle, repair and injury processes, cellular apoptosis and necrosis inductions. The results showed that resveratrol in 30 μM concentrations showed an important capability to injury NCI-H292 cells after 24 h of irradiation.

O carcinoma mucoepidermóide de pulmão, um tipo histológico que deriva das glândulas mucosas traqueobrônquicas, manifesta-se com sintomas obstrutivos e tende a comprometer a traqueia. Com finalidade curativa ou paliativa da doença, atualmente há uma forte tendência na oncologia em desenvolver estratégias terapêuticas que visam à administração de compostos com elevado potencial de otimizar o efeito do tratamento com a radiação ionizante, de modo a aumentar a morte de células tumorais e preservar íntegras as células dos tecidos sadios adjacentes. A intensa busca por tais estratégias evidenciou resultados promissores apresentados pelo composto denominado Resveratrol (3,4,5-trihidroxiestilbeno), tornando-o amplamente divulgado e alvo de intensas pesquisas. O principal objetivo do presente estudo foi determinar o efeito do resveratrol em cultura celular de carcinoma mucoepidermóide de pulmão exposta a diferentes doses de radiação ionizante. Para tal, os estudos de citotoxicidade utilizando o método de incorporação do vermelho neutro, e da determinação da dose letal 50 % (DL50) da radiação ionizante, foram realizados em cultura de células da linhagem NCI-H292 [H292] (ATCC® CRL-1848TM), CCIAL069. Com base nos resultados do IC50% (401,5 μM) e da DL50 (693 Gy) foram realizados o teste in vitro do micronúcleo e os ensaios para avaliar o efeito do resveratrol no ciclo celular, reparo da lesão no DNA e processo de lesão radioinduzida, necrose e apoptose celular. Os resultados evidenciaram que o resveratrol na concentração de 30 μM apresenta uma importante capacidade em promover danos às células NCI-H292 após 24 h da irradiação. / Mucoepidermoid lung carcinoma is a histological type that derives from the tracheobronchial mucous glands. It is manifested by trachea symptoms. Curative or palliative purpose for the disease, nowadays presents a strong oncology tendency to develop therapeutic strategies aimed at the administration of high potential compounds to improve the ionizing radiation treatments, so as to increase the radiation effects on tumor cells while minimizing these effects to surrounding normal tissues. The intensive search for such strategies showed promising results by the compound called Resveratrol, making it widely available and subject of many studies. The main of this study was to determine in vitro resveratrol effect in mucoepidermoid lung carcinoma cells NCI-H292 [H292] (ATCC® CRL-1848TM), CCIAL069, exposed to ionizing radiation doses. For this purpose, there were performed in vitro cytotoxicity studies by neutral red uptake assay, as well as the lethal dose 50 % (LD50) of ionizing radiation. On the basis of the IC50% (401.5 μM) and LD50 (693 Gy) results, there were performed in vitro micronucleus test and other tests in order to evaluate the cell cycle, repair and injury processes, cellular apoptosis and necrosis inductions. The results showed that resveratrol in 30 μM concentrations showed an important capability to injury NCI-H292 cells after 24 h of irradiation.

Orientador: Vitor Baranauskas / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Engenharia Elétrica e de Computação / Made available in DSpace on 2018-08-20T09:27:39Z (GMT). No. of bitstreams: 1 Moraes_AdrieldosSantos_M.pdf: 1300108 bytes, checksum: bcd1099ef486cc4a2842627fe2b4df57 (MD5) Previous issue date: 2012 / Resumo: A administração "in vivo" de nanotubos de carbono "multi-walled" (MWCNT's), mesmo sem serem funcionalizados, estimula o aparecimento de uma reposta imune em camundongos normais. Nesse trabalho nós fornecemos evidências de que essas nanopartículas de carbono também estimulam a resposta imune em camundongos portadores de tumor. Os MWCNT's (100 ?g) diluídos em PBS contendo 0,1 % de Pluronic 127 foram inoculados sistemicamente em camundongos portando tumores cujos tamanhos atingiram 5 milímetros (mm) e a resposta imune foi avaliada nos linfonodos desses animais. Observamos que os tumores de animais que receberam as nanopartículas não cresceram como os tumores dos animais não tratados. A discreta inibição do crescimento do carcinoma pulmonar de Lewis (LLC) foi acompanhada pela ativação de linfócitos T CD8+ tanto em número quanto em função. A ativação da função citotóxica dos linfócitos T CD8+ pode ser explicada pelo aumento da expressão de citocinas pertencentes à família da IL-12, principalmente IL-27, que é descrita como a citocina envolvida na estimulação da citotoxicidade de linfócitos T CD8+. Nossos dados demonstraram que nanotubos de carbono "multi-walled", mesmo sem funcionalização estimula resposta imunológica antitumoral / Abstract: The "in vivo" administration of multi walled carbon nanotubes (MWCNT's) even without functionalization stimulates the immune response of naïve mice. Here we provide evidence that these carbon nanoparticles also stimulated the immune response of tumor-bearing mice. The MWCNT's (100 ?g) diluted in PBS with 0,1% of Pluronic 127 were inoculated systemically in mice with tumor that reached 5 mm and the immune response was evaluated in the lymph nodes. We observed that the tumors that received the nanoparticles did not grow as the untreated tumor. The discrete inhibition of the growth of the Lewis Lung Carcinoma (3LL) was accompanied by activation of CD8 T lymphocytes both in number and in function. The activation of the cytotoxic function of CD8 T lymphocytes may be explained by the increase of expression of cytokines belongs to the IL-12 family, mainly the IL-27, which is described as a cytokines involved in the stimulation of CD8 T lymphocytes cytotoxic function. Our data demonstrated that MWCNT even without functionalization stimulated the antitumor immune response / Mestrado / Eletrônica, Microeletrônica e Optoeletrônica / Mestre em Engenharia Elétrica

No description available.

Yes / Glycogen synthase kinase-3 (GSK3) is over-expressed and hyperactivated in non-small cell lung carcinoma (NSCLC) and plays a role in ensuring the correct alignment of chromosomes on the metaphase plate during mitosis through regulation of microtubule stability. This makes the enzyme an attractive target for cancer therapy. We examined the effects of a selective cell-permeant GSK3 inhibitor (CHIR99021), used alone or in combination with paclitaxel, using an in vitro cell growth assay, a quantitative chromosome alignment assay, and a tumor xenograft model. CHIR99021 inhibits the growth of human H1975 and H1299 NSCLC cell lines in a synergistic manner with paclitaxel. CHIR99021 and paclitaxel promoted a synergistic defect in chromosomal alignment when compared to each compound administered as monotherapy. Furthermore, we corroborated our in vitro findings in a mouse tumor xenograft model. Our results demonstrate that a GSK3 inhibitor and paclitaxel act synergistically to inhibit the growth of NSCLC cells in vitro and in vivo via a mechanism that may involve converging modes of action on microtubule spindle stability and thus chromosomal alignment during metaphase. Our findings provide novel support for the use of the GSK3 inhibitor, CHIR99021, alongside taxol-based chemotherapy in the treatment of human lung cancer. / Cancer Research UK Project Grant (C16929/A14402) and the Elizabeth Blackwell Institute, through its Wellcome Trust ISSF Award (105612/Z/14/Z). The Imperial NIHR/Biomedical Research Centre and the CR-UK/Dept of Health funded Imperial Experimental Cancer Medicine Centre.

No / Background: Previous studies have shown extensive vascularisation surrounding subcutaneously implanted fibres when the duration of the US National Cancer Institute (NCI) hollow fibre assay was prolonged. Materials and Methods: The feasibility of adapting the NCI assay for evaluating agents targeting the tumour vasculature was investigated in vitro and in vivo. Finally, in the optimised assay, changes in neovasculature formation around the fibres following treatment with the anti-vascular agent paclitaxel were quantified by immunohistochemistry. Results: Correlations between cell number seeded, time in culture and vascular endothelial growth factor (VEGF) secretion were seen. In vivo studies showed that transplanting single rather than 3 fibres at a site reduced inflammation, reducing the length of the fibre transplanted, as did without any significant loss in cell growth over 21 days. A statistically significant reduction in neovascularisation surrounding the fibres was seen accompanying paclitaxel treatment. Conclusion: Modifications made here to the NCI hollow fibre assay demonstrate its potential for analysing anti-tumour vasculature agents.